News|Videos|November 14, 2023
Imaging and Staging Considerations in Renal Cell Carcinoma
Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.
Early nivolumab responders sustained years-long treatment-free survival after treatment discontinuation.
Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Advertisement
Advertisement
Trending on OncLive
1
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
2
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
3
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
4
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
5